Sign in Subscribe
COVID-19

COVID-19 Outcomes in Pediatric Hematopoietic Stem Cell Transplant Recipients Worry Researchers

Strategic Insights

— 2 min read

Recent research from the Fred Hutchinson Cancer Research Center has highlighted concerns regarding the high risk of adverse outcomes in adult and pediatric hematopoietic stem cell transplant recipients who contract COVID-19. Although children have had relatively better outcomes compared to adults, the data on risk factors and outcomes of COVID-19 among pediatric HSCT recipients are scarce. The study aimed to investigate clinical characteristics and outcomes of COVID-19 in pediatric and early adolescent and young adult hematopoietic stem cell transplant recipients.

Key Takeaways:

  • Adult hematopoietic stem cell transplantation (HSCT) recipients are at a high risk of adverse outcomes after COVID-19.
  • Children have had relatively better outcomes compared to adults, but data on risk factors and outcomes of COVID-19 among pediatric HSCT recipients are lacking.
  • The study found that overall mortality, although higher than the general population estimates, was lower when compared with previously published data focusing on adult HSCT recipients.
  • The research was funded by multiple organizations, including the United States Public Health Service, NIH National Cancer Institute (NCI), and other pharmaceutical companies.
  • The study involved a cohort of pediatric and early adolescent and young adult HSCT recipients, with the majority being males and having a median age of 16 years.
  • The most common comorbidities among the recipients were hematological malignancies, solid tumors, and genetic disorders.

Statistics:

  • 74.1% of the recipients were male, and 62.3% had a median age of 16 years.
  • The most common comorbidities were hematological malignancies (43.5%), solid tumors (24.5%), and genetic disorders (15.6%).
  • The mortality rate among the recipients was 24.2%, which was lower compared to the general population estimates.

Sources:

  • Clinical Characteristics and Outcomes of Covid-19 In Pediatric and Early Adolescent and Young Adult Hematopoietic Stem Cell Transplant Recipients: a Cohort Study. Transplantation and Cellular Therapy, 2022;28(10).
  • Fred Hutchinson Cancer Research Center.
  • United States Public Health Service.
  • NIH National Cancer Institute (NCI).
  • NIH National Heart Lung & Blood Institute (NHLBI).
  • NIH National Institute of Allergy & Infectious Diseases (NIAID).
  • United States Health Resources & Service Administration (HRSA).
  • Office of Naval Research.
  • Match Foundation.
  • General Electric.
  • National Marrow Donor Program.
  • AbbVie.
  • Accenture.
  • Takeda Pharmaceutical Company Ltd.
  • Adaptive Biotechnologies Corporation.
  • Adienne SA.
  • Allovir, Inc.
  • Amgen.
  • Astellas Pharmaceuticals.
  • bluebird bio, inc.
  • Bristol-Myers Squibb.
  • CareDx.
  • CSL Behring.
  • CytoSen Therapeutics, Inc.
  • Daiichi Sankyo Company Limited.
  • Eurofins Viracor.
  • DBA Eurofins Transplant Diagnostics.
  • Fate Therapeutics.
  • Gamida-Cell, Ltd.
  • Gilead Sciences.
  • GlaxoSmithKline.
  • HistoGenetics.
  • Incyte Corporation.
  • Iovance.
  • Janssen Research & Development, LLC.
  • Janssen Biotech Inc.
  • Jasper Therapeutics.
  • Jazz Pharmaceuticals.
  • Kadmon.
  • Karius.
  • Karyopharm Therapeutics.
  • Dexcel Pharma.
  • Kite Pharma Inc.
  • Kite (a Gilead Company).
  • Kyowa Kirin International plc.
  • Kyowa Kirin.
  • Legend Biotech.
  • Magenta Therapeutics.
  • Medac GmbH.
  • Medexus.
  • Merck & Company.
  • Millennium (the Takeda Oncology Co.).
  • Miltenyi Biotec, Inc.
  • MorphoSys.
  • Novartis.
  • Omeros Corporation.
  • OncoImmune, Inc.
  • Oncopeptides, Inc.
  • OptumHealth.
  • Orca Biosystems, Inc.
  • Ossium Health, Inc.
  • Pfizer.
  • Pharmacyclics, LLC.
  • Priothera.
  • Genzyme Corporation.
  • Seagen, Inc.
  • Stemcyte.
  • TG Therapeutics.
  • Tscan.
  • Vertex Pharmaceuticals.
  • Vor Biopharma.
  • Oce-Technologies BV.

Read more